Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Shandong Boan Biotechnology Company., Limited. Class H ( (HK:6955) ) is now available.
Shandong Boan Biotechnology said it had identified no undisclosed corporate developments behind the sharp rise in trading volume of its H shares on 9 January 2026, attributing the activity instead to on‑market transfers linked to exchangeable preference shares issued by its controlling shareholder Luye Pharma Group. Luye Pharma has been moving blocks of Boan’s H shares into a custodian account to back potential exchanges under those instruments, and has assured Boan’s board it will continue such transfers as required, while the company stressed there are no ongoing acquisition or disposal negotiations or other price‑sensitive matters requiring disclosure.
Separately, the company announced that its in‑house‑developed denosumab biosimilar injection BA6101 (60mg), already approved in China, has received marketing authorization in Bolivia, supporting Boan’s strategy to commercialize the osteoporosis treatment in multiple international markets. The product, a biosimilar to Prolia®, is under regulatory review in the UK, and the company plans further filings in Europe, the US, Japan and other jurisdictions, potentially strengthening its competitive position in global biosimilars and broadening revenue opportunities for stakeholders as international approvals progress.
More about Shandong Boan Biotechnology Company., Limited. Class H
Shandong Boan Biotechnology Co., Ltd. is a China-based biopharmaceutical company focused on the research, development and commercialization of biologics, including biosimilar drugs. Its portfolio includes in-house-developed products such as denosumab injection, targeting conditions like osteoporosis for markets in China and overseas, with an expanding global footprint across Latin America and other regions.
Average Trading Volume: 5,484,827
Technical Sentiment Signal: Sell
Current Market Cap: HK$5.9B
See more data about 6955 stock on TipRanks’ Stock Analysis page.